https://doi.org/10.55788/ca311818
Brain age is a numerical estimate of biological age, which is calculated by combining structural T1 MRI images and information about chronological age, in conjunction with artificial intelligence-based computation [1]. Dr Lars SkattebĆøl (Oslo University Hospital, Norway) aimed to validate a deep learning simple fully convoluted neural network (DL-SFCN) model for brain age in MS. The main objective was to compare DL-SFCN with an established feature-based machine learning model. To this end, eligible MRI data of 1,516 MS patients was analysed [2]. Since there is no ātrueā comparative value for a brain age estimate, Pearson's correlation and linear mixed effect (LME) modelling were used to look for associations between brain age, age, and clinical variables.
In deep learning estimations, brain age and chronological age were more firmly correlated (correlation coefficient [R]=0.90; 95% CI 0.89ā0.90) than in machine learning estimations (R=0.75; 95% CI 0.74ā0.76). Higher brain age was significantly associated with higher EDSS for deep learning estimates (t=5.3; 95% CI 0.17ā0.37) as well as machine learning estimates (t=3.7; 95% CI 0.16ā0.51), and with longer disease duration for deep learning estimates (t=5.8; 95% CI 0.08ā0.15) and for machine learning estimates (t=6.5; 95% CI 0.15ā0.28). The strongest correlation was found using longitudinal data. Clinical correlation between brain age and brain age gaps (BAG) was stronger at lower EDSS scores and was non-significant at an EDSS score of 6. The largest differences in BAG were found at an EDSS score of about 6, these differences were less prominent at lower EDSS scores.
Overall, the DL-SFCN performed equally well to the model comparator, both showing significant correlations to EDSS and disease duration. Deep learning may be of higher clinical value due to a stronger association to EDSS than machine learning.
- Franke K, et al. Neuroimage. 2010;50(3):883ā92.
- SkattebĆøl L, et al. Brain Age in Multiple Sclerosis: A comparison of traditional machine learning and deep learning methods. OPR-123, EAN 2022, 25ā28 April, Vienna, Austria.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« Ofatumumab improves cognitive processing speed Next Article
Teriflunomide in children with MS: final results of TERIKIDS »
« Ofatumumab improves cognitive processing speed Next Article
Teriflunomide in children with MS: final results of TERIKIDS »
Table of Contents: EAN 2022
Featured articles
Letter from the Editor
Overarching Theme
Migraine
Targeting cortical activation by transcranial magnetic stimulation
Erenumab more than doubles plasma CGRP levels
Over a third of patients responds late to CGRP antibodies
Multiple Sclerosis
When to start, switch, and stop MS therapy: Real-world evidence counts
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
Gut microbiota composition associated with disability worsening
Teriflunomide in children with MS: final results of TERIKIDS
Estimating brain age in MS: machine learning versus deep learning
Ofatumumab improves cognitive processing speed
Parkinsonās Disease
Intestinal alterations in patients with Parkinsonās disease
Gene variants impact survival in monogenic Parkinsonās disease
Cerebrovascular Disease and Stroke
Most acute stroke patients have undiagnosed risk factors
Absence of Susceptibility Vessel Sign points to malignancy in stroke patients
Acute stroke management: from time window to tissue window?
Epilepsy
Seizure forecasting with non- and minimally-invasive devices
Real-world efficacy of cenobamate in focal-onset seizures
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy
COVID-19
COVID-19 elevates risk of neurodegenerative disorders
More headaches in adolescents during COVID-19 pandemic
AstraZeneca vaccination and risk of cerebral venous sinus thrombosis
Large impact of COVID-19 on dementia diagnosis and care
Miscellaneous
Tau autoimmunity associated with systemic disease
Long-term effects of avalglucosidase alfa in late-onset Pompe disease
European survey of patient satisfaction in the treatment of cancer-related neuropathic pain
Related Articles
December 4, 2023
Early intensive treatment enhances long-term clinical outcomes
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com